Editas Medicine, Inc. (EDIT) stock
EDITNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 3/3035% above fair value
$2.14−0.24 (-10.08%)
Close on Nov 12, 2026Market cap $328.66MP/E –Yield –
Editas Medicine operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Editas Medicine's operating cash flow for the twelve months ending Sep 30, 2026 was -$110.21M. For fiscal 2025 it was -$165.24M. The highest annual figure on record is -$5.44M in fiscal 2015.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$165.24M | – |
| FY2024 | Dec 31, 2024 | -$210.28M | – |
| FY2023 | Dec 31, 2023 | -$132.18M | – |
| FY2022 | Dec 31, 2022 | -$177.35M | – |
| FY2021 | Dec 31, 2021 | -$163.80M | – |
| FY2020 | Dec 31, 2020 | -$179.84M | – |
| FY2019 | Dec 31, 2019 | -$40.67M | – |
| FY2018 | Dec 31, 2018 | -$45.71M | – |
| FY2017 | Dec 31, 2017 | -$9.42M | – |
| FY2016 | Dec 31, 2016 | -$50.25M | – |
| FY2015 | Dec 31, 2015 | -$5.44M | – |
| FY2014 | Dec 31, 2014 | -$8.66M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$21.19M | – |
| Q2 FY2026 | Jun 30, 2026 | -$29.57M | – |
| Q1 FY2026 | Mar 31, 2026 | -$23.06M | – |
| Q4 FY2025 | Dec 31, 2025 | -$36.39M | – |
| Q3 FY2025 | Sep 30, 2025 | -$30.84M | – |
| Q2 FY2025 | Jun 30, 2025 | -$50.21M | – |
| Q1 FY2025 | Mar 31, 2025 | -$47.80M | – |
| Q4 FY2024 | Dec 31, 2024 | -$50.76M | – |
| Q3 FY2024 | Sep 30, 2024 | -$52.59M | – |
| Q2 FY2024 | Jun 30, 2024 | -$57.06M | – |
| Q1 FY2024 | Mar 31, 2024 | -$49.87M | – |
| Q4 FY2023 | Dec 31, 2023 | -$22.24M | – |
| Q3 FY2023 | Sep 30, 2023 | -$35.46M | – |
| Q2 FY2023 | Jun 30, 2023 | -$38.71M | – |
| Q1 FY2023 | Mar 31, 2023 | -$35.77M | – |
| Q4 FY2022 | Dec 31, 2022 | -$42.27M | – |
| Q3 FY2022 | Sep 30, 2022 | -$48.00M | – |
| Q2 FY2022 | Jun 30, 2022 | -$37.85M | – |
| Q1 FY2022 | Mar 31, 2022 | -$49.23M | – |
| Q4 FY2021 | Dec 31, 2021 | -$34.58M | – |
| Q3 FY2021 | Sep 30, 2021 | -$40.79M | – |
| Q2 FY2021 | Jun 30, 2021 | -$38.96M | – |
| Q1 FY2021 | Mar 31, 2021 | -$49.48M | – |
| Q4 FY2020 | Dec 31, 2020 | -$40.10M | -197.7% |
| Q3 FY2020 | Sep 30, 2020 | -$54.80M | – |
| Q2 FY2020 | Jun 30, 2020 | -$30.86M | – |
| Q1 FY2020 | Mar 31, 2020 | -$54.09M | – |
| Q4 FY2019 | Dec 31, 2019 | $41.02M | +2991.5% |
| Q3 FY2019 | Sep 30, 2019 | -$26.88M | – |
| Q2 FY2019 | Jun 30, 2019 | -$25.81M | – |
| Q1 FY2019 | Mar 31, 2019 | -$29.00M | – |
| Q4 FY2018 | Dec 31, 2018 | $1.33M | – |
| Q3 FY2018 | Sep 30, 2018 | -$7.84M | – |
| Q2 FY2018 | Jun 30, 2018 | -$16.73M | – |
| Q1 FY2018 | Mar 31, 2018 | -$22.46M | -132.2% |
| Q4 FY2017 | Dec 31, 2017 | -$25.07M | – |
| Q3 FY2017 | Sep 30, 2017 | -$27.98M | – |
| Q2 FY2017 | Jun 30, 2017 | -$26.16M | – |
| Q1 FY2017 | Mar 31, 2017 | $69.79M | – |
| Q4 FY2016 | Dec 31, 2016 | -$13.68M | – |
See a number that looks wrong?